Login:
 
Comparing venous thrombosis risk in COCPs. Practitioner 2014;258(1767):9

Comparing venous thrombosis risk in COCPs

22 Jan 2014Registered users

Both the progestogen used and the dose of ethinylestradiol affect the venous thrombosis risk associated with combined oral contraceptive pills (COCPs), a systematic review and network meta-analysis has found. A total of 3,110 publications were retrieved of which only 25 publications reporting on 26 studies were included. Incidence of venous thrombosis in non-users from two cohorts was 1.9 and 3.7 per 10,000 woman-years which is consistent with previously reported rates of 1-6 per 10,000 woman-years. COCP use increased the venous thrombosis risk compared with non-use, relative risk (RR) 3.5, (95% CI:2.9 to 4.3). All preparations were associated with more than a two-fold increased risk of venous thrombosis compared with non-use. [With external links to the current evidence base]

Registered usersThis article can only be accessed if you are a registered user of thepractitioner.co.uk or a subscriber to The Practitioner.